<DOC>
	<DOCNO>NCT01378533</DOCNO>
	<brief_summary>The purpose trial compare 3 year DFS dose-dense epirubicin cyclophosphamide follow paclitaxel paclitaxel plus carboplatin adjuvant therapy triple-negative breast cancer . The purpose trial observe patient 's tolerance .</brief_summary>
	<brief_title>The Trial Comparing Dose-dense AC-T With PC Adjuvant Therapy TNBC</brief_title>
	<detailed_description>Breast cancer heterogeneous group tumor diverse behavior , outcome , sensitivity therapy.In recent year , term triple negative ( TN ) breast cancer emerge describe cancer express oestrogen ( ER ) , progesterone ( PR ) receptor , Her2 . Many study estimate TN case represent 12 % -20 % breast cancer . Those TN case constitute one challenging breast cancer group , systemic chemotherapy currently available treatment . BRCA1 protein normally function negative regulator cell cycle , also , BRCA1-positive tumor encompass heterogeneous group tumor show distinctive pathological clinical feature . BRCA1-associated cancer typically high-grade invasive duct carcinoma mostly triple negative.The phenotypic molecular similarity TNBCs BRCA1-associated BCs might use design treatment protocol . There increase evidence DNA repair defect characteristic BRCA-1 related cancer may provide sensitivity certain systemic agent treat TNBC patient bifunctional alkylating agent platinum drug . Dose density refers administration drug shorten intertreatment interval . It base observation experimental model , give dose always kill certain fraction , rather certain number , exponentially grow cancer cell . Because human cancer general , breast cancer particular , usually grow nonexponential Gompertzian kinetics , model extend situation . Regrowth cancer cell cycle cytoreduction rapid volume-reduced Gompertzian cancer model exponential model . Hence hypothesize frequent administration cytotoxic therapy would effective way minimize residual tumor burden dose escalation . In INT C9741 trial , dose-dense schedule accomplish use granulocyte colony-stimulating factor ( filgrastim ) permit every-2-week recycling drug A , T C optimal dose level rather conventional 3-week intervals.Sequential therapy refers application treatment one time rather concurrently . It challenge concept multiple drug need maximally perturb cancer compose cell heterogeneous drug sensitivity . Rather , hypothesize slow-growing cancer like breast cancer , important preserve dose density force combination , especially combination would toxic require dose-reductions delay drug administration . If dose density sequential combination chemotherapy regimen concurrent combination regimen , theoretical consideration indicate therapeutic result , even sequential pattern happen less toxic . In trial , want compare 3 year DFS dose-dense epirubicin cyclophosphamide follow paclitaxel paclitaxel plus carboplatin adjuvant therapy triple-negative breast cancer.The purpose trial observe patient 's tolerance .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Patient must accept modified radical mastectomy 2 . Patients histologically confirm ER ( ) PR ( ) HER2 ( ) 3 . Positive axillary lymph node ; negative axillary lymph node age＜ 35 year Ⅲ grade intravascular cancer embolus . 4 . Age 18 year 65 year 5 . Able give inform consent 6 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 7 . Not pregnant , appropriate birth control childbearing potential . 8 . Adequate bone marrow reserve ANC &gt; 1000 platelet &gt; 100,000 . 9 . Adequate renal function serum creatinine &lt; 2.0 . 10 . Adequate hepatic reserve serum bilirubin &lt; 2.0 , AST/ALT &lt; 2X upper limit normal , alkaline phosphatase &lt; 5X upper limit normal . Serum bilirubin &gt; 2.0 acceptable set know Gilbert 's syndrome . 11 . No active major medical psychosocial problem could complicate study participation . 1. receive neoadjuvant therapy 2 . Cardiac dysfunction document ejection fraction less low limit facility normal multigated acquisition ( MUGA ) scan , 45 % echocardiogram . The rate Disease recurrence 3 . Uncontrolled medical problem . 4 . Evidence active acute chronic infection . 5 . Pregnant breast feeding . 6 . Hepatic , renal , bone marrow dysfunction detail .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>triple-negative breast cancer</keyword>
	<keyword>dose-dense</keyword>
	<keyword>epirubicin cyclophosphamide follow paclitaxel（AC-T）</keyword>
	<keyword>paclitaxel plus carboplatin（PC）</keyword>
	<keyword>3 year DFS</keyword>
	<keyword>tolerance</keyword>
</DOC>